Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
(Created page with "=General information= Class/mechanism (from [http://www.cancer.gov/drugdictionary?CdrID=712549 NCI Drug Dictionary]): An orally available Raf kinase inhibitor with potential a...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
||
| Line 4: | Line 4: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Oral | + | [[Category:Oral medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Revision as of 17:03, 25 July 2017
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.